Other Comparison

Livagen vs Thymalin

Comparison of Livagen (Low evidence) and Thymalin (Moderate evidence).

Last updated: February 12, 2026

Livagen

Low Evidence
View full dossier

Thymalin

Moderate Evidence
View full dossier

Overview

Livagen and Thymalin are both studied in the peptide research space.

Livagen: A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression.

Thymalin: A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation.

Evidence Comparison

AspectLivagenThymalin
Evidence LevelLowModerate
Human Studies28
Preclinical Studies822
Total Sources1230

Key Differences

AspectLivagenThymalin
CategoryOtherImmune
Evidence StrengthLowModerate
Total Sources1230
Human Studies28

Summary

  • Livagen: Low evidence with 12 total sources (2 human)
  • Thymalin: Moderate evidence with 30 total sources (8 human)

This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.

Stay Updated on Peptide Comparisons

Get notified when we publish new comparison dossiers and evidence reviews.

No spam. Unsubscribe anytime.

Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.